Intuitive Surgical’s operating profit grew 30.7% in the second quarter of 2026 as hospitals performed more procedures using its systems. Removing a tariff refund still leaves 25.9% growth, showing that the improvement extended beyond that benefit. Stronger earnings help support expansion, but cash available for investment and share repurchases also depends on inventory spending and tax-payment timing.
Reporting basis: consolidated, unaudited financial statements prepared under U.S. generally accepted accounting principles, the accounting rules used for the reported results. Q2 covers April–June 2026; H1 covers January–June 2026. Primary filing: Form 10-Q, filed July 21, 2026, accession 0001035267-26-000058. Information cutoff: October 1, 2026; subsequent competitive developments are identified separately. Dollar tables use millions unless stated otherwise; M means million and B means billion. Company: Intuitive Surgical, Inc. (NASDAQ: ISRG).
1. Profit Improved Beyond the Tariff Refund
Intuitive’s profit improvement survives removal of the quarter’s identifiable tariff benefit, although the refund explains most of the gross-margin increase. Operating profit measures earnings after production, selling, administration, and research costs, before interest and taxes. Operating margin is that profit expressed as a share of revenue.
The comparison below removes only refunds of tariffs paid in earlier periods; it retains current tariff costs and all other reported expenses.
| Operating-profit comparison ($M, except margins) | Q2 2025 | Q2 2026 |
|---|---|---|
| Reported operating profit | 743.4 | 971.9 |
| Prior-period tariff refund removed | 0.0 | 35.9 |
| Operating profit excluding that refund, calculated | 743.4 | 936.0 |
| Reported operating margin (%) | 30.5 | 33.6 |
| Operating margin excluding that refund, calculated (%) | 30.5 | 32.4 |
Source: Q2 2026 Form 10-Q, consolidated income statement, p. 4; Item 2, “Trade and Tariffs Update” and “Gross Profit.” The refund arose in Q2 2026. The calculated comparison is not management’s adjusted earnings measure or a comprehensive estimate of recurring earnings.
The refund reduced product costs by $27.5M and service costs by $8.4M. Together, those amounts supplied 15.7% of the $228.5M increase in operating profit. Intuitive also recognized $20.8M of current-quarter tariff costs, which remain in the comparison. Recognizing a refund in earnings does not establish when the company collected the cash.
Gross margin, the share of sales left after delivering products and services, rose from 66.3% to 67.8%. Without the refund, the current margin was 66.5%, only about 0.2 percentage points above the prior year. Most of the remaining operating-margin improvement came from selling, administration, and research expenses taking a smaller share of revenue: 34.2%, down from 35.8%. Intuitive spent more on these activities, but sales grew faster, leaving more profit from each sales dollar.
1-1. Sales Outpaced Overhead Across a Longer Earnings Trend
Revenue growth translated into faster profit growth because Intuitive did not need to increase every expense at the same rate. Management attributes product-margin improvement to lower logistics costs and spreading fixed overhead across more business, alongside the refund. Higher amortization—the expense that spreads acquired intangible assets’ cost over their useful lives—partly offset those benefits.
Read the operating-margin row alongside revenue: Intuitive retained a larger share of each sales dollar over the comparison period.
| Consolidated measure ($M, except percentages) | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | 3-year CAGR (%) |
|---|---|---|---|---|---|
| Revenue | 1,755.9 | 2,009.9 | 2,440.0 | 2,892.3 | 18.1 |
| Operating profit | 463.2 | 567.3 | 743.4 | 971.9 | 28.0 |
| Operating margin (%) | 26.4 | 28.2 | 30.5 | 33.6 | — |
| Net income attributable to Intuitive | 420.8 | 526.9 | 658.4 | 818.1 | 24.8 |
| Attributable net-income margin (%) | 24.0 | 26.2 | 27.0 | 28.3 | — |
Sources: consolidated income statements, p. 4, in the 2026 10-Q, 2025 10-Q, and 2024 10-Q. CAGR is the constant annual growth rate that would connect the starting and ending values, calculated here across three annual intervals. These are quarterly comparisons, not full-year results. Margins and growth rates are calculated. Attributable net income excludes the earnings belonging to minority owners of the consolidated joint venture.
Selling, general, and administrative expenses increased 10.1% to $617.9M, below revenue growth of 18.5%. Research and development rose 18.3% to $370.6M, broadly matching sales growth. Research spending remained an expense in reported profit rather than being excluded from the analysis. Management identified personnel and infrastructure costs as important spending drivers.
This is operating leverage: sales grew faster than the costs needed to support them, allowing profit to grow faster still. Here, operating-profit growth was roughly 1.66 times revenue growth. That ratio describes the quarter; it does not predict the profit response to future sales. The filing does not provide a complete fixed-versus-variable cost split, and the tariff refund strengthens the reported relationship.
1-2. Higher Taxes Absorbed Part of the Operating Gain
Net income grew more slowly than operating profit because taxes rose and interest and other income declined. Attributable net income increased 24.3% to $818.1M. Interest and other income fell from $88.7M to $82.7M, while the effective tax rate—the share of pretax earnings recorded as tax expense—rose from 20.2% to 21.9%.
Excess tax benefits from employee equity awards fell from $32.9M to $17.3M in Q2. These benefits arise when tax deductions for settled or vested awards exceed their accounting expense. The H1 comparison was more pronounced: the effective tax rate increased from 8.8% to 17.3%, while those benefits fell from $178.3M to $90.6M. Consequently, H1 attributable profit grew 20.8%, well below operating-profit growth of 38.3%. These award-related tax benefits should not be treated as a stable operating advantage.
Diluted earnings per share, which includes potential shares from employee awards and other dilutive instruments, rose from $1.81 to $2.29. Calculated before rounding, profit growth contributed about $0.44 of the increase at the prior share count. A lower diluted share count contributed another $0.04. The weighted-average denominator fell from 364.1M to 357.3M shares, reflecting the combined effects of repurchases, employee issuance, and potential share dilution.
Sources: 2026 10-Q, p. 4, Notes 11–12, and Item 2, operating expenses and income taxes.
2. More Procedures Support Revenue, but Equipment Growth Includes Replacements
Intuitive’s growth is supported by greater use of its systems, not simply by delivering more machines. Da Vinci supports minimally invasive surgery; Ion helps physicians obtain lung tissue samples. Both create repeat demand for instruments and related services after installation.
The useful comparison is between procedure growth, the installed equipment base, and new placements. The installed base counts systems at customers; placements count systems supplied during the quarter, including sales and leases. Placements can replace existing equipment, so they are not the same as additions to the installed base.
| Operating indicator | Q2 2025 | Q2 2026 |
|---|---|---|
| Worldwide da Vinci procedure growth, year over year (%) | 17 | 15 |
| Da Vinci installed base at June 30, approximate (systems) | 10,488 | 11,710 |
| Da Vinci placements during quarter (systems) | 395 | 468 |
| Placements involving trade-ins or lease upgrades, as described below (systems) | 83 | 144 |
| Ion placements during quarter (systems) | 54 | 55 |
| Instruments and accessories revenue ($M) | 1,474.1 | 1,734.9 |
| Service revenue ($M) | 391.2 | 472.4 |
Sources: 2026 10-Q, Note 5 and Item 2, procedures and system placements; 2025 10-Q, Item 2. The 2026 filing labels its placement subset “trade-ins”; the 2025 filing described the corresponding 83 units as “trade-ins or lease upgrades.” The subset is not a measure of net installed-base additions. Procedure growth figures are management’s approximate estimates.
Instrument and accessory revenue increased 17.7%, helped by procedure volumes and a favorable shift in the mix of instruments sold toward da Vinci 5 and single-port systems. Service revenue increased 20.8%. Intuitive classified $2.47B, or approximately 85% of quarterly revenue, as recurring, including operating leases. That description captures repeated use and support revenue; it does not mean every dollar is contractually guaranteed.
Da Vinci utilization, measured as procedures per system per year, increased approximately 3%. Procedure growth alongside higher utilization supports the case that hospitals are using additional capacity. However, worldwide procedure growth slowed from approximately 17% to 15%. U.S. growth was approximately 12%, while growth outside the U.S. was approximately 20%.
The equipment comparison contains substantial replacement activity. Total da Vinci placements increased by 73 units, while the reported trade-in subset increased by 61. With the disclosure wording qualification above, placements outside that subset increased from 312 to 324. The evidence supports continued expansion and upgrading, but does not establish where the overall replacement cycle stands.
Ion presents a different pattern: procedure volumes rose approximately 36%, while placements barely increased. Management says U.S. customers increasingly focus on using existing systems more intensively. That supports demand for instruments used in procedures, but suggests equipment shipments need not match procedure growth. Combining Ion and da Vinci placements into one growth measure would obscure this distinction.
Source: 2026 10-Q, Item 2, “Procedures,” system placements, and instruments and accessories revenue.
3. Cash Generation Improved, While Buybacks and Expansion Drew on Reserves
Operating cash flow increased substantially, but investment and share repurchases still reduced available liquidity. Operating cash flow is the cash generated by running the business; it differs from accounting profit because payment dates and noncash expenses differ.
The first three rows show cash remaining after direct purchases of property and equipment; the remaining rows explain wider cash movements.
More cash remained after capital spending
| Cash measure ($M) | H1 2025 | H1 2026 | Change ($M) |
|---|---|---|---|
| Operating cash flow | 1,297.0 | 1,972.9 | 675.9 |
| Property and equipment purchases, positive spending | 271.9 | 215.9 | -56.0 |
| Free cash flow, calculated | 1,025.1 | 1,757.0 | 731.9 |
| Investing cash flow | 474.2 | -941.1 | -1,415.3 |
| Financing cash flow | -383.6 | -1,641.6 | -1,258.0 |
| Cash paid for common-share repurchases | 181.0 | 1,443.5 | 1,262.5 |
| Acquisition, net of acquired cash, intellectual property, and other investing outflow | 1.2 | 528.2 | 527.0 |
| Ending cash, cash equivalents, and restricted cash | 3,446.5 | 2,805.7 | -640.8 |
Source: 2026 10-Q, consolidated cash-flow statement, p. 5. Free cash flow equals operating cash flow less property and equipment purchases. Investing cash flow includes those purchases; the rows must not all be added together. The acquisition row combines several investing activities and is not the acquisition’s standalone purchase price. The ending-cash comparison is June 2026 versus June 2025, not the change during H1 2026. Restricted cash is included in that row but is not freely available for general spending.
3-1. Tax Timing Helps Explain the Higher Cash-to-Profit Ratio
Operating cash flow rose relative to profit, but noncash adjustments contributed materially to the reconciliation between them. Operating cash flow divided by consolidated net income increased from 0.82 in H1 2024 to 0.95 in H1 2025 and 1.20 in H1 2026. In other words, the latest period produced about $1.20 of operating cash for each dollar of accounting profit.
The matching inputs were operating cash flow of $885.9M, $1,297.0M, and $1,972.9M, against net income of $1,078.9M, $1,367.9M, and $1,649.2M. Crossing 1.0 does not by itself establish that earnings became more reliable.
The deferred-tax adjustment swung from negative $29.4M to positive $370.3M. This reconciles tax expense recognized in profit with its different cash-payment timing. The $399.7M swing was a large contributor to the cash-flow reconciliation, but is not itself cash received or an independently measured tax saving.
Meanwhile, prepayments and other operating assets absorbed $179.0M. Management primarily links that movement to prepaid taxes arising from accelerated deductions of research costs previously recorded as assets for tax purposes. It expects these prepayments to reduce future cash tax payments. The deferred-tax adjustment and prepaid-tax movement should not be counted as two separate cash windfalls.
Inventory absorbed $514.6M, and compensation liabilities absorbed $229.7M, largely through payment of prior-year incentives. Depreciation and disposal losses added back $371.2M, while the cash-flow statement added back $419.4M of share compensation. These adjustments remove expenses that reduced profit without using the same amount of cash during the period. Together with changes in operating assets and liabilities, they explain why cash generation cannot be inferred directly from the profit-growth rate.
Sources: 2026 10-Q, p. 5 and Item 2, “Operating Activities”; 2025 10-Q, p. 5, for H1 2024.
3-2. Leasing Investment Extends Beyond the Capital-Spending Line
The $215.9M property-purchase line does not capture all resources committed to equipment. Intuitive also transferred $419.3M of equipment, including systems for customer operating leases, from inventory into property and equipment. The transfer itself was noncash. Cash used to produce that inventory affects operating cash flow when paid; it need not occur in the same period as the transfer.
The transfer should therefore not be subtracted a second time from free cash flow. Direct capital spending was 3.8% of H1 revenue, but that ratio alone misses the leasing business’s asset requirements. Management describes investment in infrastructure to scale the business and inventory to support leasing and supply continuity. The filing does not disclose a split between spending to maintain existing capacity and spending to expand it.
Customer leases lower the upfront purchase burden for hospitals and can support adoption. They also leave Intuitive funding systems while revenue arrives over time. Usage-based arrangements expose the company to low utilization and early cancellation. That is why procedure growth matters to both revenue and recovery of equipment costs.
Source: 2026 10-Q, p. 5 and Item 2, system leasing and capital expenditures.
3-3. Repurchases Reduced Shares but Used Most Remaining Operating Cash
Buying back and retiring shares increases remaining shareholders’ ownership per share and can raise earnings per share. Employee awards work in the opposite direction by adding shares. The benefit therefore needs to be assessed against both dilution and the cash committed.
Intuitive paid $1.44B for repurchases in H1, using 82.2% of calculated free cash flow. It recorded $1.51B of repurchases and retired approximately 3.2M shares; cash settlement and equity recognition occurred at different times. At June 30, $63.5M of repurchases remained accrued and unpaid, representing a cash obligation beyond the amount already paid.
Outstanding shares fell from 355.1M to 353.9M after employee issuance and share withholding—a net reduction of 1.2M shares, smaller than the number repurchased. The $4.7B remaining authorization at June 30 permits additional repurchases but creates no payment obligation by itself.
Free cash flow covered repurchases, but adding the acquisition and related investing outflow left a funding gap.
| Selected cash uses and coverage ($M) | H1 2026 |
|---|---|
| Free cash flow, calculated | 1,757.0 |
| Cash paid for common-share repurchases | 1,443.5 |
| Acquisition, net of acquired cash, intellectual property, and other investing outflow | 528.2 |
| Cash remaining after these uses, calculated | -214.7 |
Source: 2026 10-Q, p. 5. The final row subtracts the two cash outflows from free cash flow; it is not the total change in cash and excludes other investment and financing movements. The acquisition row is a combined cash-flow category, not the standalone purchase price. Unpaid repurchases are excluded from these cash-paid figures.
Free cash flow exceeded cash repurchases by $313.5M, leaving less than the acquisition-related outflow required. Employee-plan proceeds of $187.4M were more than offset by $365.4M paid for employee share-settlement taxes. No common cash dividend appears in the period’s financing statement.
These choices were manageable given Intuitive’s liquidity, but buybacks competed with business investment for cash. Repeating the same combination would require continued cash generation or further use of reserves. Sources: 2026 10-Q, pp. 5 and 19, Note 9, and Item 2, liquidity.
4. Financial Reserves Remain Substantial as Expansion Adds Assets and Costs
Intuitive retains substantial financial capacity despite its cash outflows. Cash plus short- and long-term investments totaled $8.63B at June 30, down from $9.03B at year-end. The balance sheet reports no separate bank borrowing or bond balance.
The asset changes below show where resources accumulated as liquid funds declined.
| Consolidated balance-sheet item ($M) | December 31, 2025 | June 30, 2026 | Change (%) |
|---|---|---|---|
| Cash and cash equivalents | 3,368.0 | 2,760.4 | -18.0 |
| Accounts receivable, net | 1,527.3 | 1,673.2 | 9.6 |
| Inventory | 1,840.0 | 2,028.7 | 10.3 |
| Property and equipment, net | 5,342.4 | 5,551.5 | 3.9 |
| Intangible and other assets, net | 848.7 | 1,140.1 | 34.3 |
| Goodwill | 370.3 | 580.6 | 56.8 |
| Total assets | 20,458.7 | 20,876.6 | 2.0 |
| Total liabilities | 2,517.0 | 2,578.9 | 2.5 |
| Total equity, including noncontrolling interests | 17,941.7 | 18,297.7 | 2.0 |
Source: 2026 10-Q, consolidated balance sheet, p. 3. “Intangible and other assets” is the reported combined category, not a standalone intangible-assets balance. Percentage changes are calculated.
4-1. The European Acquisition Added Assets and Ongoing Amortization
Direct distribution gives Intuitive greater control over customer service, training, and product deployment. It also brings sales infrastructure and integration costs onto its own accounts. Intuitive completed its purchase of the da Vinci and Ion distribution businesses serving Italy, Spain, Portugal, and associated territories on March 1, 2026.
The preliminary allocation included $91.8M of receivables, $60.5M of property and equipment, and $218.0M of goodwill. Goodwill represents acquisition value beyond separately identified net assets. Identified acquired intangibles totaled $219.4M, predominantly customer relationships. Their amortization spreads the acquisition cost through future earnings.
The acquired receivables contributed to the balance-sheet increase, but the transaction also settled $32.6M of existing receivables. The acquired balance therefore cannot be treated as a complete explanation of the change, or as evidence that customer collections slowed. Likewise, inventory transfers into leased equipment help explain why the inventory balance rose less than the operating cash absorbed. Acquisition accounting and transfers must be considered before treating those movements as changes in routine trading activity.
Intuitive expects higher amortization and depreciation during the remainder of 2026. Depreciation spreads the cost of physical assets, such as equipment and buildings, over their useful lives. Those expenses create a continuing cost hurdle even if sales keep rising. Management said the acquisition’s standalone revenue and earnings were not significant for disclosure purposes, so a quantified acquisition return is not supported.
Sources: 2026 10-Q, Note 7 and Item 2; March 2 acquisition announcement.
4-2. Equity Grew Even as Share Transactions Reduced Retained Earnings
The fall in retained earnings—accumulated profits remaining in the equity accounts—reflects deductions for share transactions rather than a business loss. Retained earnings moved from $7,011.8M to $6,837.2M. H1 attributable profit added $1,639.6M, while share retirement and employee tax withholding deducted $1,459.5M and $354.7M, respectively.
Common stock and additional paid-in capital, the equity accounts recording share issuance and related capital, increased from a combined $10,768.9M to $11,325.4M, helped by employee plans and share compensation. Accumulated other comprehensive income fell from $43.3M to $5.8M, reflecting valuation and currency-translation movements recorded outside net income. Total equity still increased by $356.0M. Assets reconcile to $2,578.9M of liabilities plus $18,297.7M of equity.
The liability burden is primarily operational. Accounts payable rose from $255.1M to $277.2M, while total deferred revenue rose from $598.1M to $662.0M. Deferred revenue represents customer billings before Intuitive completes the associated service or delivery; $20.0M came with the acquisition. Its increase does not establish longer customer contracts.
The interim report does not separately quantify the assets and obligations arising from property or equipment Intuitive itself rents. These should not be confused with equipment it owns and leases to hospitals. The latter supports customer revenue and appears within operating assets.
Source: 2026 10-Q, p. 3 and Notes 4–6 and 9.
4-3. Competition Now Overlaps With Important Procedure Categories
New competition raises the importance of training, reliability, and hospital economics in sustaining growth. After the reporting period, Johnson & Johnson announced U.S. authorization for OTTAVA on July 22. Its authorized procedures include gallbladder removal and appendectomy, which overlap with categories supporting Intuitive’s U.S. growth. J&J described an initial launch with selected U.S. customers. J&J announcement, July 22, 2026.
That creates a credible source of future hospital purchasing competition, but does not demonstrate lost Intuitive procedures or revenue. An initial selective launch also differs from immediate deployment at scale. The practical test is whether Intuitive maintains utilization and instrument revenue as hospitals gain alternatives. Its direct-distribution expansion and continued research spending support customer service and product development, although their competitive payoff remains to be demonstrated.
4-4. Tariff Refunds May Not Repeat, While Potential Legal Losses Remain Unquantified
The refund should not become a permanent margin assumption. Intuitive says most instruments manufactured in Mexico qualify for the relevant trade exemption, limiting exposure there. Other imports and supplier costs remain exposed. Holding quarterly revenue constant, removing the $35.9M refund benefit alone reduces operating margin by approximately 1.2 percentage points, before any other changes.
Legal exposure could also affect the business. Note 8 identifies a reasonable possibility of product-liability losses beyond recorded amounts, but provides no estimable range. Instrument servicing and replacement are also subjects of antitrust litigation. The consolidated class action was scheduled for trial on September 14, 2027, as disclosed in the filing.
The litigation record also includes favorable rulings for Intuitive. The court ruled for the company on Surgical Instrument Service Company’s antitrust claims in January 2025 and dismissed Restore Robotics Repairs’ case in November 2025. Both plaintiffs appealed; those appeals remained unresolved in the filing’s account.
These rulings temper an assessment based only on pending claims, but do not eliminate exposure. The cases concern both potential payments and business practices surrounding instruments and repairs. The inability to estimate losses is not evidence that exposure is zero, and no quantified earnings adjustment is justified by the available disclosure.
Source: 2026 10-Q, Note 8, pp. 16–18, and Item 2, tariff discussion; litigation status stated as of that filing.
5. Continued Procedure Use Matters More Than Repeating the Refund
Intuitive’s stronger operating result is supported by procedure growth and slower overhead growth, even after the tariff refund is removed. This is a medical-technology adoption business with exposure to hospital equipment budgets. The multiyear earnings record supports expansion, while the latest procedure slowdown argues against assuming acceleration.
The central operating challenge is to preserve profit growth as depreciation, acquisition amortization, and competition increase. Removing the refund leaves a 32.4% operating margin, above the 30.5% earned a year earlier. Sustaining that improvement depends on repeated instrument sales and productive use of installed systems. A future decline in utilization or instrument revenue growth would weaken that assessment more directly than a single quarter of equipment placements.
Funding capacity remains substantial, but cash allocation deserves equal attention. H1 free cash flow covered repurchases, yet did not cover repurchases plus the acquisition-related investing outflow. Tax timing also contributed materially to the reconciliation between profit and operating cash flow. Continued expansion is financially supportable; repeating large buybacks alongside acquisitions would consume more of the reserve unless cash generation rises.
The clearest evidence of further progress would be stable or rising utilization, margin strength without comparable refunds, and cash generation after inventory and tax movements settle. Conversely, heavier selling costs or weaker procedure economics under competition would narrow the earnings benefit from expansion. The present evidence supports a profitable growth business able to fund investment through operating cash and existing reserves. Its operating improvement extends beyond the tariff refund, but the refund’s contribution to the quarter’s margin should not be assumed to repeat.
Calculation notes: editorial percentage changes use the amounts disclosed in the filing, with calculations rounded only at the end; the filing’s own percentage changes may use underlying figures with greater precision. Margins divide the stated profit measure by consolidated revenue. The refund-only calculation subtracts $35.9M from both operating profit and gross profit, without estimating a net-income tax effect. The earnings-per-share decomposition holds diluted shares at 364.1M for the profit contribution, then changes the denominator to 357.3M. Cash-to-profit ratios use consolidated net income including noncontrolling interests, matching the cash-flow statement. No future earnings, cash-tax benefit, or acquisition return is assumed.
This analysis is based on filings submitted to the U.S. Securities and Exchange Commission and is provided for informational purposes only. It is not investment advice. Source: SEC Form 10-Q, filed July 21, 2026.